The Primary And Secondary Levofloxacin、Moxifloxacin Resistance To Helicobacter Pylori

Background： Levofloxacin and moxifloxacin are newly used in the Helicobacter pylorieradication treatment, however the increasing resistant rates threaten the efficacy oferadication therapy. There are few researches on the levofloxacin and moxifloxacinresistance of Helicobacter pylori, as well as the risk factors about the resistance in ourcountry.Objective： The aim of this study is to assess the primary and secondary resistance ofHelicobacter pylori strains to levofloxacin and moxifloxacin，which isolated from patientsof Fuzhou, China, and characterize the risk factors associated with these two antimicrobials.Methods： In total,60H.pylori strains were isolated, of which,38strains obtained frompatients without any history of eradication, while the remaining22strains obtained frompatients with a failed fluoroquinolone-containing therapy. The minimal inhibitionconcentration of levofloxacin and moxifloxacin was examined by E-test. Primary andsecondary resistance of these two antibiotics was evaluated, and risk factors for theantibiotics resistance were analyzed.Results：①Thirty percent(18/60) of the strains obtained were resistant to levofloxacin, whileThe average antibiotic resistant rate of moxifloxacin is31.67%(19/60). Seventeenstrains(28.33%) resistant to both levofloxacin and moxifloxacin.②The primary andsecondary resistant rates to levofloxacin were15.79%and54.55%respectively, thesecondary rates was higher than the primary one (P=0.002). And the secondary resistant rateto moxifloxacin was significantly higher than primary rate (18.42%vs54.55%,P=0.004).③Multivariable analyzes showed that the resistance of levofloxacin andmoxifloxacin were associated with age and previous eradication treatment history.Conclusions:(1).There were high resistant rates both of levofloxacin andmoxifloxacin.(2)The secondary resistant rate to levofloxacin and moxifloxacin was significant higher than the primary one.(3)Age and the previous treatment withfluoroquinolone were individual risk factors for development resistance of both levofloxacinand moxifloxacin.